Superparamagnetic iron oxide (SPIO) MR imaging contrast agents are extremely strong enhancers of proton relaxation. These superparamagnetic agents have been the subject of extensive research over the past decade. While many of them are still in clinical trial or experimental study stages, a few products have been marketed [1, 2, 3] . SPIO agents include a wide range of preparations whose physico-chemical properties differ greatly. This article reviews these agents' physicochemical properties, bio-distribution and clinical applications, which include bowel contrast, liver and spleen imaging, lymph node imaging, bone marrow imaging, perfusion imaging and MR angiography. Receptor-directed imaging and magnetically labeled cell probe MR imaging are also under experimental study [4, 5, 6]. The clinical applications of various specific SPIO agents indicated in this review are based on the most recent literature, however their applications will be extended upon further research. The agents exploiting the paramagnetic property of the soluble iron ion for contrast are not reviewed in this article. Eur. Radiol. (2001) Abstract Superparamagnetic iron oxide MR imaging contrast agents have been the subjects of extensive research over the past decade. The iron oxide particle size of these contrast agents varies widely, and influences their physicochemical and pharmacokinetic properties, and thus clinical application. Superparamagnetic agents enhance both T1 and T2/T2* relaxation. In most situations it is their significant capacity to reduce the T2/T2* relaxation time to be utilized. The T1 relaxivity can be improved (and the T2/T2* effect can be reduced) using small particles and T1-weighted imaging sequences. Large iron oxide particles are used for bowel contrast [AMI-121 (i.e. Lumirem and Gastromark) and OMP (i.e. Abdoscan), mean diameter no less than 300 nm] and liver/spleen imaging [AMI-25 (i.e. Endorem and Feridex IV, diameter 80±150 nm); SHU 555A (i.e.
Abstract Superparamagnetic iron oxide MR imaging contrast agents have been the subjects of extensive research over the past decade. The iron oxide particle size of these contrast agents varies widely, and influences their physicochemical and pharmacokinetic properties, and thus clinical application. Superparamagnetic agents enhance both T1 and T2/T2* relaxation. In most situations it is their significant capacity to reduce the T2/T2* relaxation time to be utilized. The T1 relaxivity can be improved (and the T2/T2* effect can be reduced) using small particles and T1-weighted imaging sequences. Large iron oxide particles are used for bowel contrast [AMI-121 (i.e. Lumirem and Gastromark) and OMP (i.e. Abdoscan), mean diameter no less than 300 nm] and liver/spleen imaging [AMI-25 (i.e. Endorem and Feridex IV, diameter 80±150 nm); SHU 555A (i.e. (Fig. 1A) . Superparamagnetism occurs when crystal-containing regions of unpaired spins are sufficiently large that they can be regarded as thermodynamically independent, single-domain particles. These single-domain particles are named magnetic domains (Fig. 1B) . Such a magnetic domain has a net magnetic dipole that is larger than the sum of its individual unpaired electrons [7, 8] . In the absence of an applied magnetic field, such magnetic domains are free to rotate from thermal motion, and are randomly oriented with no net magnetic field ( Fig. 2A ). An external magnetic field can cause the magnetic dipoles of the magnetic domains to reorient, analogous to paramagnetic materials (Fig. 2B ). The magnetic moments 1 of such magnetic domains reflect interacting unpaired electrons; the resultant magnetic moment is much greater than that of a paramagnetic substance, and the specific magnetic susceptibilities 2 of these particulates can significantly exceed those of corresponding soluble paramagnetic species because of this magnetic ordering [7, 8] . Superparamagnetic substances lack remnant magnetization when the external magnetic field is terminated, as the magnetic moment of the individual magnetic domains loose their collective orientation and the net magnetic moment becomes zero. That means SPIO agents will not self-aggregate due to magnetic attraction. Superparamagnetism has an obligatory crystalline nature; superparamagnetic agents will therefore necessarily be particulate [1] .
Both T1 and T2/T2* relaxation processes are shortened by SPIO. MR contrast agents' relaxivity 3 is typically measured at 37 C and 0.47 T. The T2 relaxivity of 100 mmol ±1 l s ±1 and T1 relaxivity of 30 mmol ±1 l s ±1 of typical SPIO agent are substantially larger than the relaxivity of paramagnetic molecules such as Gd-DTPA (T2 relaxivity of 6 mmol ±1 l s ±1 and T1 relaxivity of 4 mmol ±1 l s ±1 ) [9] . The observed effects on signal intensity depend on various factors, including particle composition, particle size, concentration of particles within a given imaging voxel, and data acquisition parameters. Accordingly the clinical doses of SPIO agents may vary with imaging sequences. The magnetic field applied has also a non-linear influence on the signal, however this property is not so important in clinical practice [1] . In most situations, it is SPIO agents' significant capacity to reduce the MRI signal to be utilized, which can be emphasized by using spin echo sequences with a longer echo time (TE) and by using gradient-echo sequences. However, when particulates of smaller sizes are used and T1W sequences are chosen, their T1 relaxation shortening property is emphasized [10, 11] . Sometimes the decrease in signal intensity caused by SPIO agents can be so pronounced that it can cause distortion or obliteration of organ boundaries. This effect of magnetic susceptibility, also called ªbloomingº, can be mitigated by specifying data acquisition parameters that have less T2 or T2* dependence.
The typical synthesis of SPIO agents involves controlled precipitation of iron oxide in an aqueous solution of ferrous salt, ferric salt and coating material 2320 Fig. 1 Schematic representation of A spinal crystal structure for superparamagnetic iron oxide (SPIO) domain; B SPIO crystal with multiple magnetic domains of random orientation and C complete SPIO contrast agent particle, with multiple SPIO crystals and coating materials 1 Magnetic moment is a measurement of the magnetic properties of a dipole, which interacts with an applied magnetic field such as a bar magnet. Magnetic moment is one factor that determines the efficiency of proton relaxation enhancement of an agent. 2 Magnetic susceptibility is the tendency of a substance to become magnetized or to distort an applied magnetic field. Magnetic susceptibility causes signal loss and, when severe, causes geometric distortion on MR images.
(dextran or others) by addition in drops of an alkaline solution while active stirring or sonication is applied. The SPIO agents are then isolated by differential centrifugation and dialyzing [1, 10, 12, 13] . SPIO agents are thus often composed of both an active SPIO component (iron oxide crystals, which vary in size from agent to agent and also depend on the measurement technique; their sizes are generally between 4 and 10 nm), and a coating material (Fig. 1C) . The total particle size (including the iron oxide crystals and the coating material) in solution can be larger than the dry size, due to the absorbed, hydrated coating dextran layer. To describe the particle size, usually hydrodynamic diameter is used. Hydrodynamic diameter is derived from dynamic light scattering techniques which calculate average solution particle sizes by monitoring the diffusion characteristics of the particles in solution. The resulting solution particle sizes are the diameters of hypothetical spheres with the same diffusion coefficients as the SPIO aggregates with their adsorbed, solvated coating materials. The mean diameters of injectable particles vary from 1 mm to less than 10 nm [1, 5, 14, 15] . Since the injected particles are much smaller than erythrocytes (approximately 7 mm in diameter), they easily traverse capillary beds.
The size of the particle, the charge and the nature of the coating determine the stability, bio-distribution and metabolism of SPIO agents [16] . Although most superparamagnetic particles are coated with dextran or dextran derivatives, they can also be coated by other composites, such as starch, albumin, and arabinogalactose. These composites are bio-compatible, thus permitting safe intravenous administration and ready biodegradability. Since SPIO particle uptake into the reticuloendothelial system (RES) is related to protein absorption on the particle surface and subsequent opsonization, minimizing the particle surface will result in a decreased protein absorption, which reduces particle phagocytosis, finally resulting in a significant increase in plasma halflife and wider bio-distribution [17] .
As SPIO agents degrade, the iron enters the plasma iron pool and is subsequently incorporated into red cell production and other natural uses of iron. Eventually it is secreted from the body as the body iron stores turn over. The smaller size of particles accelerates degradation of SPIO into paramagnetic forms of iron. The amount of iron oxide that would be required for clinical MR imaging is small compared with the physiological iron stores [1, 18] . Compared with other MR agents, SPIO agents' toxicity is low. Extensive toxicity studies in animals have disclosed no acute toxicity or chronic injury at doses greater than 100 times the clinical effective dose [19] .
Classification of superparamagnetic iron oxide agents
Superparamagnetic iron oxide contrast agents include oral (large) SPIO agents, standard SPIO (SSPIO) agents, ultrasmall SPIO (USPIO) agents and monocrystalline iron oxide nanoparticle (MION) agents. The former three kind of agents have been approved for clinical application or are being clinically tested, under various generic names and trade names (Tables 1 and 2 ). MION agents are still at the experimental study stage. Injectable SPIO agents are colloidal suspensions containing invisible particles. These particles will remain in suspension and do not settle out from the solution because the energy of Brownian motion largely surpasses the strength of gravity, and, in an external magnetic field, also that of magnetic attraction. To ensure no aggregated particles will be injected, some SPIO agents are introduced via a 5 mm filter. Larger particles in temporary dispersion, such as some agents for bowel contrast, may settle spontaneously upon storage [1] . Oral superparamagnetic iron oxide agents Oral SPIO preparations usually contain larger particles than do injectable agents. They are coated with a nonbiodegradable and insoluble matrix (siloxane for AMI-121 and polystyrene for OMP), and suspended in viscosity-increasing agents (usually based on ordinary food additives, such as starch and cellulose) [1, 20] . These preparations can prevent the ingested iron from being absorbed, and particles from aggregating, and improve homogeneous contrast distribution throughout the bowel. If SPIO particle aggregating occurs, magnetic susceptibility artifact may result, especially when high field strength and gradient echo pulse sequences are used. Two oral SPIO agents (AMI-121 and OMP) have been tested in clinical trials. Oral SPIO agents are used as negative contrast agents, i.e. they decrease signal on T2W images. AMI-121 (Lumirem by Guerbet and Gastromark by Advanced Magnetics) is composed of crystal of approximately 10 nm; the hydrodynamic diameter is approximately 300 nm. The relaxivities are 72 and 3.2 mmol ±1 l s ±1 respectively, for T2 and T1 relaxivity. The recommended concentration is 1.5±3.9 mmol ±1 l Fe [20] .
OMP (Abdoscan, Nycomed) is composed of crystal of below 50 nm. The total particle size is 3.5 mm. The particles contain 25 % iron oxide w/w, the concentration of OMP is 0.5 g/l [1] .
Oral SPIO is normally administered over 30±60 min, with a volume of 900 ml for contrast enhancement of the whole abdomen, and 400 ml for imaging of the upper abdomen. Oral SPIO suspensions are well-tolerated by the patients: the iron is not absorbed and the intestinal mucosal membrane is not irritated [1, 20] . . AMI-25 efficiently accumulates in the liver (approximately 80 % of the injected dose) and spleen (5±10 % of the injected dose) within minutes of administration; the blood half-life is 6 min [22] . Peak concentrations of iron were found in liver after 2 h and in the spleen after 4 h. Iron is slowly cleared from liver (half-life, 3 days) and spleen (halflife, 4 days) [22] . AMI-25 preparation is usually not bolus-injected because of cardiovascular side effects and lumbar pain. The recommended mode of administration is a dose of 15 mmol Fe/kg in 100 ml of glucose 5 % and a biphasic infusion (2 ml/min over 10 min and 4 ml/min over 20 min). AMI-25 allows a wide scan window for T2/T2*W imaging (0.5~6 h after administration) [2] . SHU 555A (Resovist, Schering AG) is a SSPIO characterized by a carbodextran rather than dextran coating. The crystal of SHU 555A is 4.2 nm and the hydrodynamic diameter is 62 nm. The T2 and T1 relaxivities are 151.0 and 25.4 mmol ±1 l s ±1 respectively. Unlike AMI-25, Resovist does not show side effects after rapid intravenous injection (performed by preloading SHU 555A into a connecting intravenous line and flushing the line with 10 ml saline for 3 s). A dose of 8 mmol Fe/kg is the recommended quantity for liver T2W imaging at retention phase (after the SPIO particles have been trapped by the phagocytes), which can be scanned 30 min after administration [18] . Due to its smaller size and thus stronger T1 relaxation property, SHU 555A has also been used for T1W imaging and MR angiography. Dynamic T1W MR imaging following bolus infusion of SHU 555A mimics signal changes caused by gadolinium chelates [2] . Significant vessel T1 relaxation enhancement can be achieved at a dose of 10 mmol Fe/ kg [2] .
Ultrasmall superparamagnetic iron oxide agents AMI-227 (Sinerem by Guerbet and Combidex by Advanced Magnetics) is composed of a crystalline core of 4±6 nm surrounded by dextran coating. The hydrodynamic diameter is 20±40 nm. Their relaxivity is similar to the prototype of USPIO [9, 23] . Despite the slightly larger size of AMI-277 compared with the prototype USPIO, AMI-277 has a much longer plasma halflife due to improved coating. In humans, the blood pool half-life of plasma relaxation times is calculated to be more than 24 h [23]. Because of its long blood half-life and significant T1 relaxation effects, AMI-277 can be used as blood pool agent during the early phase of intravenous administration [25, 26, 27] . In the late phase, AMI-277 is suitable for the evaluation of RES in the body, particularly in lymph nodes [28, 29] . A dose of 13.8±29.2 mmol Fe/kg is used for MR angiography. The clinical dose of AMI-277 for MR lymphography can range from 29.2 to 44.7 mmol Fe/kg; usually with fast spin echo (SE) sequences a high dose is used and with gradient echo sequences a low dose is used [30] . AMI-277 is not bolus-injected, rather, it should be infused slowly over a period of 30 min to avoid hypotensive reactions or acute lumbar pain.
NC100150 (Clariscan, Nycomed) is a type of USPIO developed for MR angiography and perfusion study [31] . It has an iron oxide core of 5±7 nm diameter, and a carbohydrate-polyethylene glycol coating. The total particle is 20 nm. The T2 and T1 relaxivities are 35 and 20 mmol ±1 l s ±1 respectively. The vascular half-life is dose-dependent and ranges from 3 to 4 h [24, 31]. The low value of T2 relaxivity/T1 relaxivity Ratio (1.8) of this formulation is favorable for T1 relaxation enhancement. The agent has been shown to be safe in humans when administered intravenously as a bolus in doses up to 172 mmol Fe/kg. The optimal dose for MR angiography is 50±100 mmol Fe/kg; it allows prolonged delineation (> 45 min) of vasculatures as observed by MR angiography [31] . Brain T2*W perfusion study has been tested at a dose of 7 mmol Fe/kg [19] .
Currently, Schering AG is also developing a USPIO, SHU 555C, with a mean diameter of £20 nm. SHU 555C is bolus-injectable and can be used for MR angiography and perfusion imaging. [32, 33] Monocrystalline iron oxide nanoparticles Monocrystalline iron oxide nanoparticles differ from other iron oxide preparations in their monocrystallinity, which fulfills the criteria for receptor-directed MR imaging and magnetically labeled cell probe MR imaging agent due to its very small size (2.8 9 nm). MIONs can easily pass through capillary endothelium while retaining superparamagnetism [14, 15] . Initial studies used gadolinium chelates as receptor-directed agent but very high levels of this contrast agent were needed to significantly reduce proton relaxation times, which make gadolinium chelates less practicable. MIONs provide higher magnetic susceptibility (two to three orders of magnitude) than gadolinium. It has been stated that in vivo detection with MR imaging is possible at concentration as low as 1 mg Fe/g tissue [14, 15] . Targeted MR imaging with MION is still in the experimental stage, but may prove to be a powerful tool for cellular and molecular MR imaging in the future.
Application of superparamagnetic iron oxide agents for bowel contrast MR bowel contrast is better done with negative agents rather than positive agents [3] . Negative bowel agents decrease the extent of noises and motion artifacts related to bowel peristalsis, but on the other hand, positive agents increase these noises and artifacts, especially with slower scanners [1] . The use of negative oral SPIO agents giving rise to a signal void from the intestinal loops may reinforce the visualization of intra-abdominal lesions, both on T2W images, where the lesions often appear hyperdense, and in T1W images in association with injection of a gadolinium chelate.
Bowel opacification may be helpful in certain specific circumstances, such as in the evaluation of pancreatic diseases and in the delineation of bowel pelvic abnormalities. Negative oral SPIO agents can also improve the quality of images obtained with MR urography and MR cholangiopancreatography, by eliminating unwanted signals from fluid contained in adjacent bowel loops [34] .
Application of superparamagnetic iron oxide agents in reticuloendothelial system imaging
After intravenous administration, SSPIO and USPIO particles are taken up by RES cells; their value in liver and lymph node MR imaging has been well-established. Due to their prominent RES cell phagocytosis and T2 relaxivity, SSPIO agents show a stronger signal loss in the liver and spleen than do USPIOs. However, high doses of smaller SPIOs can still achieve a comparable enhancement for liver and spleen imaging as obtained by SSPIOs [35]. The diagnostic utilities of SPIO-enhanced MR imaging for other normal tissues and lesions with phagocyte involvement are also under investigation.
Liver and spleen imaging
After intravenous administration, SSPIOs are cleared from the blood within minutes, rapidly accumulating in the RES cells of liver and spleen. With T2W sequences the presence of SPIO particles decreases signal intensity of normal parenchyma of liver and spleen. Focal lesions without RES cells usually maintain nearly the same signal intensity before and after the administration of the SSPIO. There is consensus now that SSPIO-enhanced MR imaging significantly increases tumor-to-liver contrast, and improves lesion conspicuity and detectability on T2W images [36] . It has been reported that ferumoxide-enhanced MR imaging has a sensitivity for metastatic lesion detection of 95 % [37] . In a large multicenter trial, additional liver lesions were identified on 27 % of ferumoxide-enhanced images compared with unenhanced scans [38] . However, it should be noted that the presence of phagocytic cells within early stages of hepatocellular carcinoma might cause enhancement comparable with adenomatous hyperplasia.
Efforts exploiting smaller SPIOs' T1 effects during liver MR imaging have also been reported. Dynamic T1W perfusion imaging of SHU 555A and AMI-277 provides information of the vascularity of liver solid lesions similar to that by Gd chelates, e.g. hypervascular hepatocellular lesions may demonstrate an initial signal increase [2, 39] . MR angiography of the liver artery and portal venous system can be performed with these agents during the accumulation phase (when SPIO particles are being trapped by phagocytes in the organs), showing increased vascular signal by a suppression of background liver signal [40] .
Though hemangiomas do not contain Kupffer cells, with both distribution phase images (while contrast agents remain in circulation) and retention phase images, hemangiomas demonstrated greater SPIO uptake than malignant neoplasms. Due to the SPIO's T1 relaxivity, on distribution phase T1W SE images hemangiomas may show signal enhancement and become bright [41] . The degree of enhancement on T1W images and drop in signal intensity on T2W images were significantly higher in hemangiomas than in malignant liver masses [42, 43] .
Experimental studies showed SPIO-enhanced MR imaging might be valuable in assessing hepatic function via observation of phagocytotic activity. SPIO-enhanced MR imaging was compared with rat models of allogeneic and syngeneic liver transplantation. Uptake of SPIO was decreased in the acutely rejecting livers but was normal in the syngeneic transplantation model [44] . SPIO-enhanced MR imaging can detect the range and extent of liver injury a few days after irradiation [45] . However, it was also reported that the dose-dependency and rate of decay of efficacy of SPIO in cirrhosis were similar to those in normal liver [46, 47] . Further studies are warranted to establish finally the role of SPIO-enhancement in assessing liver function.
SPIO-enhanced MR imaging is also able to improve the detection of diffuse and focal splenic disease [48] .
Lymph node imaging
The diagnosis of lymph node metastases is difficult without proper contrast agents. Metastatic nodes vary in diameter, and signal intensities of metastatic nodes do not differ from those of normal nodes. Normal-sized metastatic nodes cannot be differentiated from large reactive nodes. With SPIO-enhanced MR imaging, metastatic nodes can be differentiated from normal nodes based on the absence of signal intensity change between pre-and post-contrast scans [29] .
After intravenous administration, USPIO is taken up by macrophages within lymph nodes and therefore reduces the signal of normal functioning nodes on T2/ T2*W images. Metastatic nodes that are partially or completely replaced by tumor cells do not possess the same levels of phagocytotic activity as normal nodes, and maintain the same signal intensity on post-contrast MR images. With SPIO-enhanced MR imaging, a sensitivity of 95 % and specificity of 84 % have been reported for diagnosing tumor-bearing lymph nodes [28] . Normal-sized metastatic nodes, which would have been missed if size criteria alone had been used, can be detected [49] . The rare false-positive results had been reported to be related to well-encapsulated necrotic nodes, reactive follicular hyperplasia of lymph node with scarce macrophages, and heterogeneous microstructural distribution of iron oxide particles within the lymph node [29] . Differentiation between reactive and tumor-bearing lymph nodes is also possible: reactive lymph nodes contain functional macrophages and can be enhanced [50] .
The optimal time for post-contrast imaging is 24 h after SPIO administration [30] . Because the USPIO is administered intravenously, lymph nodes through the entire body can be imaged with a single injection.
To administer these agents by subcutaneous or intramuscular injection is also feasible. Under these conditions lymphatic drainage transports the contrast agent to the lymph nodes close to the injection site.
Bone marrow imaging
Bone marrow MR imaging has a high sensitivity for detection of marrow lesions. However focal lesion detection can be difficult in situations in which the uninvolved marrow is richly cellular, such as in infants and children, and in adults with red marrow hyperplasia. Marrow areas representing islands of regenerating red marrow may mimic focal marrow lesions. The administration of USPIO that could assess bone marrow phagocytic activity is useful in differentiating phagocytic normal marrow from abnormal marrow, where phagocytic function is altered.
Experimental studies have shown that bone marrow RES uptake of the intravenously injected USPIO is sufficient to reduce the signal of bone marrow MR imaging. Maximum decrease in relaxation times of marrow occurred within 1±24 h after intravenous administration. USPIO-enhanced MR imaging improves detection of smaller tumors and allows differentiation of tumor deposits from islands of hyperplastic or normal red marrow [51] . USPIO may accumulate in a zone of inflammation outside the tumor margin. A hypointense zone outlined the tumor margins on post-contrast T2W imaging improved visualization of the soft tissue component of the larger lesions [52, 53] .
Radiation-induced alterations of the blood-bone marrow barrier and the RES activity can also be studied with USPIO-enhanced MR imaging. The bone marrow enhancement increases significantly following irradiation, corresponding to alterations of the endothelial lining of the bone marrow sinusoids and increased RES activity [54] .
It had been reported that AMI-25, a type of SSPIO, could also decrease the relaxation times of human normal vertebral marrow. It was suggested that the amount of small particles contained in AMI-25 are phagocytosed by the marrow RES [55] .
Macrophage activity in neoplasms of the hematopoietic system can persist despite marrow infiltration, and the enhanced pattern of these lesions may be the same as normal marrow.
Reticuloendothelial system imaging at other sites Experimental studies showed SPIO-enhanced MR imaging might increase the detecting capability of some central nervous system diseases with phagocytes involvement. In experimental encephalomyelitis, lesions had been seen by T2W MR imaging as low signal intensities after USPIO administration. Acute early lesions measuring only 100 mm in diameter could be detected. Electron microscopy revealed the presence of iron particles within the cytoplasm of macrophages at the lesion sites [56, 57] .
Hauger et al. [58] reported the detection of kidney macrophage infiltration with USPIO-enhanced T2W MR imaging in a rat model of experimental nephropathy. A significant signal decrease was observed in the nephropathy kidneys after USPIO enhancement.
Recently Ruehm et al. [59] reported the possibility of imaging atherosclerotic plaque in rabbits aorta with AMI-277 enhancement. It was found that AMI-277 particles were phagocytosed by macrophages in atherosclerotic plaques and may lead to MR imaging-detectable signal change.
Experimental studies also demonstrated substantial uptake and transport by axons after intraneural injection of MIONs modified with a strong surface charge or covalently linked to neurotropic protein. Numerous Schwann cells and macrophages acquired large fractions of the injected agents. The nerves appeared on T2W MR images as hypointense structures [60, 61] .
Application of superparamagnetic iron oxide agents for MR angiography
The main advantage of using blood pool agents for MR angiography is that it allows a longer acquisition time window and there is less interstitial background enhancement. Reports about studies with USPIO for MR angiography in humans have been published since 1996. Stillman et al. [25, 26] reported that AMI-277 improved visualization of renal artery lengths and right coronary artery. Mayo-Smith et al.
[27] studied the aorta, the inferior vena cava and the portal vein in 16 patients before and 45 min after administration of AMI-227. All vessels showed significant enhancement at 45 min. There was no significant increase in noise or signal intensity of muscle after contrast.
It had been reported that the degree of experimental common carotid artery stenosis, determined by NC100150-enhanced MR angiography, did not differ significantly from digital subtraction angiography (DSA), whereas time of flight (TOF) and phase contrast (PC) MR angiography underestimated it [24] . The image quality of the NC100150-enhanced MR angiography was superior to both unenhanced TOF and PC MR angiography [24] . In the phase I clinical study reported by Taylor et al. [62] , NC 100150 was given safely to 18 healthy subjects for coronary MR angiography enhancement. Coronary artery delineation was improved with no major adverse reactions. High-quality MR angiograms of the pulmonary vasculature had been obtained with NC100150 injection, permitting complete visualization and excellent delineation of central, segmental, and subsegmental arteries [63] . Following iatrogenic injury in the two animals, pulmonary hemorrhage was readily detected [64] .
NC100150 was also tested in a gastrointestinal bleeding animal model. It was shown that all bleeding sites were readily detected and localized on MR images while contrast material accumulated in the intestines and peritoneal space. The extent of the bleeding can be determined with repeat data acquisitions [65] .
Contrast enhanced MR angiography is also feasible with SHU 555A, a type of SSPIO with relatively smaller size [2] .
Application of superparamagnetic iron oxide agents for tissue perfusion imaging
Because of their high susceptibility, bolus-injectable USPIO agents are very suitable as perfusion study agents. Gadolinium chelates have been used for perfusion study by dynamic susceptibility contrast imaging. However, to stay within the recommended dose limit of 0.3 mmol/kg, current Gd-based contrast agents can only be administered a limited number of times in doses necessary for perfusion imaging. This limits the possibility for serial measurements with short time periods. USPIO agents have a low toxicity and hence provide the possibility of repeated measurement.
Brain perfusion imaging and functional imaging
Dynamic USPIO-enhanced susceptibility imaging is able to detect ischemic cerebral injury at an early stage. Magnetic susceptibility effects of iron particles cause low signal in normally perfused cerebral tissue, whereas tissue with reduced or absent blood flow continues to give relatively high signal [66] . Reproducible and comparable perfusion measurements had been obtained by using NC100150 at a dose of 7 mmol Fe/kg and Gd-DTPA at a dose of 200 mmol/kg [19] . The utility of a steady-state technique for continuous measurement of relative cerebral blood volume during global transient ischemia and subsequent hyperemia had been demonstrated, which permits continuous, in vivo mapping of alterations in cerebral blood volume [67] .
By sensitizing the signal to cerebral blood volume changes, SPIO agents may increase the sensitivity of MR imaging to physiological variations in cerebral blood volume, thus making it useful for brain function imaging [68, 69] .
Myocardial perfusion imaging
Contrast agents may improve the detection of the myocardial infarction region when cardiac edema is minimal. Extracellular contrast media (CM) are sub-optimal perfusion markers, as these agents equilibrate rapidly throughout the interstitial space, thereby hampering the exact delineation of hypoperfused areas. Rozenman et al. [70] studied the effect of SPIO on myocardial T2W MR imaging with rat models. It was demonstrated that myocardial signal intensity decreased following SPIO infusion in normal hearts. The intensity remained constant in the rat heart transplants during coronary occlusion, both before and after the infusion of SPIO, and decreased upon reperfusion. There was a larger effect of SPIO in reperfused myocardium than in normal myocardium, suggesting the presence of ischemia-induced hyperemia. Thus the use of SPIO permits identification of normal, ischemic, and reperfused myocardium. By using T1W MR sequence, the effect of SPIO as T1 enhancing agents in the investigation of a myocardial perfusion defect has also been reported. Compared with normal myocardium, the ischemic myocardial region appeared as a lower and delayed enhancing area [71] . Absolute quantification of myocardial tissue perfusion has been performed in pigs with left coronary anterior descending branch stenoses using NC100150. A high absolute quantification correlation was found between MR perfusion imaging and microsphere quantification [72] .
The feasibility of improving myocardial/blood pool contrast in MR cine images through use of NC100150 was tested in human subjects. Larger image intensity gradients at the endocardial border were expected to improve the capabilities of automated segmentation algorithms, reducing the uncertainty and need for manual editing [73] .
Kidney perfusion imaging
The use of USPIO-enhanced MR imaging in assessing renal function has been studied by experiments. Trillaud et al. [74] studied first-pass intrarenal hemodynamics with USPIO-enhanced MR imaging of rabbit kidney. It was found that the intravascular progression of the US-PIO particles could be visualized within the cortex, the outer and inner compartments of the medulla. The enhancement was reduced and delayed in the kidneys, with ligation of the lumbar ureter or embolization of the renal artery. USPIO-enhanced MR was also used in the rabbit model of glycerol-induced acute renal failure. In the acute renal failure kidneys, contrast enhancement in the outer and inner medulla was significantly less than in the normal kidneys [75] .
Tumor vascularity perfusion
Tumor sprouted vessels can be greater in both number and diameter than in their healthy counterparts. This abnormal vascularity can be studied and quantified in vivo by SPIO-enhanced perfusion study.
The potential of T2/T2*W USPIO-enhanced MR imaging to characterize rat brain glioma vascularization has been evaluated. The DR2* variations due to the injection of the contrast agent were used to generate relative cerebral blood volume [76] . Dennie et al. [77] reported that DR2*/DR2 increases as vessel size increases, and can be used as a measure of the average vessel size within a region of interest (ROI) or a voxel. This ratio compared favorably with a predicted ratio calculated from histologically determined vessel sizes and theoretical modeling results. (DR2 and DR2* are the differences between T2 and T2* relaxation rates 4 pre-and post-contrast agent injection).
Human hepatocellular carcinoma vascularity was evaluated with SHU 555A-enhanced susceptibility-sensitive echoplanar sequences. Transient decreases in tumor signal intensity were seen in the perfusion phase. These decreases in signal intensity were different for poorly differentiated, moderately differentiated and well-differentiated hepatocellular carcinoma, with poorly differentiated tumors showing the strongest signal decreases and well-differentiated tumors showing the mildest signal decreases [78] .
Superparamagnetic iron oxide agents for receptordirected MR imaging and magnetically labeled cell probe MR imaging
Most receptor-directed agents and magnetically labeled cell probes use MIONs. MIONs can pass through capillary fenestra and inter-endothelial junctions to reach the extra-vascular space. This passage is a prerequisite for these targeted imagings.
The concept of development of a small superparamagnetic probe conjugated to antibody was first presented by Weissleder and colleagues [14, 15] For tumor-specific imaging, monoclonal antibodies specific to carcinoembryonic antigen [79] , epidermal growth factor receptors [4] , human glioma cell-surface antigen [80] , and other antigens [81, 82] have been attached to MION. Their efficacy has been established in ex vivo studies and animal studies.
The expression of tumor markers on tumor cell surfaces is not a static situation but changes with the evolution of the type and amount of antigen presented over time. An approach aiming at the highest possible specificity also bears a high risk of less sensitivity. The use of a less-specificity mechanism related to cell proliferation, such as angiogenesis-associated factors, has also been proposed. Human transferrin has been coupled to MION. A combination of the SPIO relaxivity properties with the specificity of transferrin-mediated endocytosis allowed in vivo detection of tumors by MR imaging [5] .
MIONs have also been labeled with materials expressing high affinity for receptors of normal tissue cells. MION was attached to cholecystokinin for MR receptor imaging of normal rat pancreas. Bio-distribution studies showed a significant enhancement in pancreatic tissues but not in tumor after administration of this complex [83] . Arabinogalactan-coated MION and asialofetuincoated MION target the contrast agent exclusively to hepatocytes. These agents can be used to assess focal hepatic lesions as well as haptocyte function [84, 85] .
By incubation with a variety of cells with MIONs, these cells can be efficiently labeled with MION particles via endocytosis uptake [86, 87] . This technique may be used for MR imaging of in vivo cell tracking. Dynamic MR tracking of rat T-cells labeled with MION has been performed successfully in rat testicles, with tissue inflammation induced by the local injection of a calcium ionophore to attract T-cells [88] . MION-labeled neutrophils have also been tested as inflammation-specific contrast agents for MR imaging [6] . Uptake of SPIOs by neutrophils and monocytes and these cells' ability to aggregate in the inflamed site is related to the size and coating of the MIONs [89] .
Conclusion
The introduction of SPIO agents opens up an important field of research for scientists, industries and clinical radiologists. AMI-25 enhanced MR imaging using T2/ T2*W sequences following slow infusion of the contrast agent has been shown to improve the detection of focal liver lesions, compared with non-enhanced MRI and contrast-enhanced CT. Recently developed bolus-injectable SPIO agents such as SHU 555A enable more versatile approaches to be made for liver imaging by means of dynamic imaging. A combination of T1 and T2/T2*W imaging provides more useful information than T2/T2*W imaging alone. The clinical value of US-PIO-enhanced lymph node MR imaging has been established; approval of these agents will lead to wide application for the diagnosis of lymph node metastasis. The blood pool property of the smaller SPIO agents may be used in MR angiography of difficult vessels such as coronary arteries, and in perfusion imaging. Though the final clinical relevance of receptor-directed MR imaging and magnetically labeled cell probe MR imaging remains far from established, these techniques may fundamentally change the practice of MR imaging, leading to the assessment of tissue function at the cell and molecular levels. However, further wider application of bowel contrast is not expected, due to intrinsic good soft tissue resolution of MR imaging with modern scanners. As extremely high doses were used in many experimental studies of RES imaging for diseases such as autoimmune encephalomyelitis and atherosclerotic plaque, the question of how these results can be extrapolated to humans remains uncertain [90] .
The further development of SPIO-enhanced MR imaging depends on improved knowledge of the fundamental mechanism of SPIO agents on MR signals, and the pharmacokinetic control of these agents, including appropriate selection of particle charge, size and coating, linking these agents with molecules capable of accurate specific targeting, and development of new imaging sequences. 
